Last reviewed · How we verify
Vaccination Provision 2
Vaccination Provision 2 is a Biologic drug developed by Queen's University. It is currently in Phase 1 development.
Unfortunately, there is not enough information provided to write a factual summary of Vaccination Provision 2. The provided facts do not mention Vaccination Provision 2, but rather mention a study on the effect of extended yellow fever vaccine information and a general mention of Vaccination Provision.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Vaccination Provision 2 |
|---|---|
| Sponsor | Queen's University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Addressing the Double Burden of Malnutrition in Guatemala (NA)
- Supporting the National Expansion of HPV-based Cervical Cancer Screening in Tanzania Among Women Living with HIV (NA)
- Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors (NA)
- Multilevel Interventions to Enhance Provider Recommendations for HPV Vaccination (NA)
- Livestock for Health Project (NA)
- An Adolescent Health and Wellbeing Check-up Programme in Three African Cities (Y-Check) (NA)
- Simulation-Based Stress Inoculation Training (NA)
- Evaluation of an Interactive Risk Information Tool to Increase COVID-19 Vaccination Incidence in Vaccine-hesitant People (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaccination Provision 2 CI brief — competitive landscape report
- Vaccination Provision 2 updates RSS · CI watch RSS
- Queen's University portfolio CI
Frequently asked questions about Vaccination Provision 2
What is Vaccination Provision 2?
Who makes Vaccination Provision 2?
What development phase is Vaccination Provision 2 in?
Related
- Manufacturer: Queen's University — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing